People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. | — | Biotechnology | Series C | $90.8M | $3.7B | 2018 |
Gene M. Liau at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gene M. Liau on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth L. Harrison | 1 | 4 |
| Huw Nash | 1 | 1 |
| Adrian Krainer | 1 | 1 |
| Isabel Aznarez | 1 | 1 |
| Barry M. Ticho | 1 | 1 |
| Charles R. Allerson | 1 | 1 |
| Adrian R. Krainer | 1 | 1 |
| Edward M. Kaye | 1 | 1 |
| Samuel W. Hall | 1 | 1 |
| Meena R. Meena | 1 | 1 |
| Arthur A. Levin | 1 | 1 |
| Arthur W. Tzianabos | 1 | 1 |
| Isabel M. Aznarez | 1 | 1 |
| Huw M. Nash | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.